2don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Stocktwits on MSN3d
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays StoicShares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $ ...
Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Shares of AbbVie Inc. ABBV tumbled 12.57% to $174.43 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.10% to 6,001.35 ...
I last wrote on AbbVie Inc. (NYSE:ABBV) back in September 2024 and on Pfizer Inc. (NYSE:PFE) back in August 2024. These articles are titled “AbbVie: Dividend Discount Model Suggests Large ...
Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback